ProBio Trial: Niraparib Plus Abiraterone Shows Greater Clinical Benefit in BRCA-Mutated mCRPC

/in , , /by

New findings from the randomized phase 3  ProBio platform trial suggest that niraparib combined with abiraterone and prednisone may extend clinical benefit in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying homologous recombination repair (HRR) gene alterations, particularly BRCA1/2 mutations. However, no overall survival advantage was demonstrated. The analysis included 99 patients, with 54 receiving […]

Read more

PEACE-1: Triplet Therapy Shows Lasting Survival Benefit at Eight Years

/in , , /by

After a median follow-up of 7.7 years, the phase 3 PEACE-1 trial confirms a lasting survival benefit from adding abiraterone and prednisone to standard treatment for men diagnosed with metastatic hormone-sensitive prostate cancer. The trial enrolled 1,173 men and tested the addition of abiraterone, prostate radiotherapy, or both to androgen deprivation therapy (ADT), with or […]

Read more

Phase 3 Trial for 177Lu-ludotadipep Radioligand Therapy for mCRPC

/in , , /by

A new phase 3 trial is testing 177Lu-ludotadipep (177Lu-FC705 or, simply, FC705), an experimental PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). Unlike 177Lu-PSMA-617 (Pluvicto), ludotadipep includes an albumin-binding component designed to keep the radioligand in circulation longer and increase radiation delivery to PSMA-positive tumours. Earlier studies suggest that this strategy may allow substantial […]

Read more

Phase 2/3 Trial Will Test BAT Followed by Darolutamide

/in , , , /by

A newly registered randomised phase 2/3trial will test an unusual strategy in metastatic androgen pathway modulation-resistant prostate cancer (mAPMR; formerly mCRPC or castration-resistant prostate cancer): deliberately exposing resistant cancer cells to very high testosterone levels before attacking the androgen receptor again with darolutamide. The study plans to enrol 432 patients with mCRPC who have already […]

Read more

Phase 2/3 Trial For 68Ga-DOTA-RM2: GRPR-Targeted PET Could Open the Door to a New Theranostic Platform

/in , , , , , , /by

PSMA has transformed prostate cancer imaging and radioligand therapy, but it is not the only useful target on prostate cancer cells. A new pivotal trial, SPARROW, is now testing 68Ga-DOTA-RM2, a PET tracer that targets the gastrin-releasing peptide receptor, or GRPR, in men with prostate cancer. The study is designed to determine how accurately GRPR-PET […]

Read more

STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer

/in , , , , /by

A multicentre, randomised trial published in The Lancet Oncology shows that a supervised, behaviourally supported lifestyle programme can measurably blunt the adverse effects of androgen deprivation therapy (ADT) for prostate cancer. Called STAMINA, the study enrolled 700 men on ADT across 15 NHS trusts in England and randomly assigned them in a 5:4 ratio to […]

Read more

Phase 3 Trial Tests a New B7-H3 Strategy in Advanced Prostate Cancer

/in , , /by

A new phase 3 clinical trial is preparing to evaluate risvutatug rezetecan, or Ris-Rez or GSK5764227, in men with metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that continues to progress despite androgen-deprivation treatment. The study, called EMBOLD Prostate-302, will compare this experimental therapy with best supportive or standard care, potentially including the […]

Read more

UPDATE: Phase 3 Pivotal Trial for 177Lu-NYM032

/in , , /by

A PSMA-targeted radioligand built on a compound called NYM032 is heading into the pivotal phase 3 trial that will decide whether its early data hold up. The molecule can be labeled with gallium-68 for PET imaging or lutetium-177 for therapy, giving a matched diagnose-and-treat pair. In mouse tumor models, escalating the dose from 18.5 to […]

Read more

Pluvicto Moves Into First-Line Metastatic Prostate Cancer, Marking Shift Toward Earlier Radioligand Therapy

/in , , , /by

A new regulatory approval is reshaping the treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC), bringing radioligand therapy into much earlier stages of disease. Pluvicto (lutetium Lu-177 vipivotide tetraxetan aka 177Lu-PSMA-617), a therapy targeting prostate-specific membrane antigen (PSMA), can now be used in combination with standard androgen deprivation therapy and androgen receptor pathway inhibitors in […]

Read more

EvoPAR‑Prostate05 Phase 3 Trial: Saruparib Maintenance for Metastatic Hormone‑Sensitive Prostate Cancer

/in , , /by

EvoPAR‑Prostate05 is a Phase 3 maintenance trial testing the PARP1‑selective inhibitor saruparib (AZD5305) in men with metastatic hormone‑sensitive prostate cancer (mHSPC). The trial enrolls both HRR‑mutated and non‑HRR‑mutated patients but requires that each participant has confirmed homologous recombination repair mutation status (HRRm – genes such as BRCA1, BRCA2, ATM, PALB2, CDK12, RAD51B/C/D, or BARD1), homologous […]

Read more